Although the KRISTINE trial results have not changed the standard of care for the neoadjuvant management of HER2 + BC [35], it was reported that a 71% pCR rate was achieved by docetaxel + carboplatin + trastuzumab + pertuzumab (4 cycles) followed by trastuzumab emtansine (T-DM1) + pertuzumab (4 cycles) regimen [36]. This evidence concerns the gene ERBB2 and breast cancer.